Retatrutide Research

Retatrutide: Spellings, Codes and What Each Finds

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library1 min readLast reviewed 2026-08-233 cited sources

The short answer

Retatrutide is the INN, LY3437943 the development code, and reta an informal abbreviation. The codes most easily confused with it are Lilly's own: LY3298176 is tirzepatide and LY3502970 is orforglipron.

Key facts

INN
Retatrutide
Development code
LY3437943
Informal
Reta
Easily confused
LY3298176: tirzepatide
Also confusable
LY3502970: orforglipron
Finds research
Retatrutide, LY3437943
Finds market content
Reta

The three names and what each returns

Retatrutide finds the peer-reviewed literature and the trial registrations. LY3437943 finds the same plus earlier development-era records, including the Coskun discovery paper's title. Reta finds forum and commercial content almost exclusively, because no researcher uses it.

The confusion that actually causes errors

Not spelling, but the Lilly codes. LY3437943, LY3298176 and LY3502970 are retatrutide, tirzepatide and orforglipron respectively. Three similar codes, one company, three compounds at different regulatory stages. This library found two real errors from exactly this: a tirzepatide PubChem record cited as retatrutide, and orforglipron's ATTAIN-1 trial labelled as retatrutide's TRIUMPH-1.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why the trial names are also confusable

TRIUMPH is retatrutide's Phase 3 programme; SURMOUNT is tirzepatide's; ACHIEVE and ATTAIN are orforglipron's. All are Lilly programmes with similar naming conventions running concurrently. Checking which compound a registration names, rather than trusting the programme name, is the only reliable approach.

Hyphenation and case

LY3437943, LY-3437943 and LY 3437943 all appear and signal nothing. Retatrutide is not hyphenated. None of these variations carries information about the compound.

The practical rule

Verify the compound named in any record before citing it. A number that looks right is not evidence that it is right. Both of this library's errors involved identifiers that appeared entirely plausible, from the correct company, in the correct format, pointing at the wrong molecule.

Quick reference

CodeCompoundStatus
LY3437943RetatrutideInvestigational
LY3298176TirzepatideApproved
LY3502970OrforglipronApproved (UK, Aug 2026)

Frequently asked questions

Is 'reta' used in research?

No. It appears in commercial and forum content. Papers use retatrutide or LY3437943.

What is the most common source of confusion?

Lilly's three similar development codes: LY3437943, LY3298176 and LY3502970 are three different compounds at three different regulatory stages.

How do I avoid citing the wrong one?

Check the compound named in the record itself. A plausible-looking identifier from the right company can still point at the wrong molecule.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.